2023
Transgender People’s Experiences Sharing Information With Clinicians: A Focus Group–Based Qualitative Study
Alpert A, Mehringer J, Orta S, Hernandez T, Redwood E, Rivers L, Manzano C, Ruddick R, Adams S, Sevelius J, Belanger E, Operario D, Griggs J. Transgender People’s Experiences Sharing Information With Clinicians: A Focus Group–Based Qualitative Study. The Annals Of Family Medicine 2023, 21: 408-415. PMID: 37748898, PMCID: PMC10519763, DOI: 10.1370/afm.3010.Peer-Reviewed Original ResearchConceptsCommunity-based participatory research approachFocus groupsSafety of clinical careTransgender peopleFamily medicine cliniciansInterpretive description methodologyParticipatory research approachQualitative focus groupsData collection toolSuboptimal careTransgender people's experiencesSubstandard careHealth informationClinical encountersDescriptive methodologyPeer debriefingClinical careClinicians' questionsQualitative studyPurposive samplingMedical cultureCareCommunity membersTransgender adultsMedical system
2022
Experiences of Transgender People Reviewing Their Electronic Health Records, a Qualitative Study
Alpert A, Mehringer J, Orta S, Redwood E, Hernandez T, Rivers L, Manzano C, Ruddick R, Adams S, Cerulli C, Operario D, Griggs J. Experiences of Transgender People Reviewing Their Electronic Health Records, a Qualitative Study. Journal Of General Internal Medicine 2022, 38: 970-977. PMID: 35641720, PMCID: PMC10039220, DOI: 10.1007/s11606-022-07671-6.Peer-Reviewed Original ResearchConceptsElectronic health recordsExperiences of transgender peopleHealth recordsAudio-recordings of focus groupsFocus groupsElectronic health record documentationPatients immediate accessTransgender peopleInterpretive description methodologyPatient-clinician rapportPatient-clinician relationshipCommunity-engaged researchResultsFour themesDesignQualitative studyOpenNotes movementQuality careDigital audio recordingsCentury Cures ActClinician notesStigmatized patientsDescriptive methodologyReduce harmSnowball samplingPurposive samplingCures ActAn international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert A, Olszewski A, Kim S, Hess B, Gaballa S, Ayyappan S, Castillo J, Argnani L, Voorhees T, Saba R, Chowdhury S, Vargas F, Reis I, Kwon D, Alexander J, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link B, Logothetis C, Herrera A, Friedberg J, Kahl B, Luminari S, Zinzani P, Lossos I. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances 2022, 6: 2035-2044. PMID: 35196377, PMCID: PMC9006265, DOI: 10.1182/bloodadvances.2021006844.Peer-Reviewed Original ResearchConceptsProgression-free survivalEastern Cooperative Oncology GroupMALT-IPIRituximab maintenanceOverall survivalHerpes zosterAssociated with longer progression-free survivalPerformance status 0 to 1Associated with shorter progression-free survivalHeterogeneous non-Hodgkin lymphomasPresence of B symptomsLonger progression-free survivalShorter progression-free survivalExtranodal marginal zone lymphomaOccurrence of herpes zosterMarginal zone lymphomaInternational Prognosis IndexNon-Hodgkin's lymphomaAdvanced-stage diseaseCooperative Oncology GroupStandard-of-careAdverse prognosis factorsAssociated with occurrenceImpact OSUpfront regimens